The company is also developing additional revenue streams, such as its intellectual property (IP) incubator, which selects and nurtures IPs to expand into areas like events and merchandise.
PhillipCapital analysts Liu Miaomiao and Paul Chew have kept “buy” on 17Live with a lower target price of $1.80 from $2.30 previously following the company’s 1HFY2024 ended June results release.
In their Aug 19 paid report, the analysts highlight 17Live’s revenue in virtual liver (V-Liver) live streaming, which more than tripled in 1HFY2024 to US$4.8 million. This is due to the onboarding of more streamers incentivised by low-cost V-Liver skins.
